Morphologic and Molecular Prognostic Markers in Prostate Cancer

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Advances in Anatomic Pathology

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00125480-200203000-00003PMID 11917165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mucinous adenocarcinoma of the prostate gland.

  2014cited by this paper
• Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics

  2005cited by this paper
• Prostate cancer — biology of metastasis and its clinical implications

  2004cited by this paper
• Role of p27 in Prostate Carcinogenesis

  2004cited by this paper
• Prognostic factors in prostate cancer.

  2003cited by this paper
• Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens.

  2001cited by this paper
• Development of a dual monoclonal antibody immunoassay for total human kallikrein 2.

  2001influential reference
• Prostate cancer: screening and early detection.

  2001cited by this paper
• Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis

  2001influential reference
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  2000cited by this paper
• The Role of E-Cadherin-Catenin Complex: More Than an Intercellular Glue?

  2000cited by this paper
• Serum interleukin 6 as a prognostic factor in patients with prostate cancer.

  2000cited by this paper
• Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.

  2000cited by this paper
• Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.

  2000influential reference
• Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers.

  2000cited by this paper
• Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.

  2000cited by this paper
• Apoptosis in prostate carcinogenesis

  2000cited by this paper
• Development of markers of prostate cancer metastasis

  2000cited by this paper
• Transforming Growth Factor-ß1 and Prostate Cancer

  2000cited by this paper
• Complex cadherin expression in human prostate cancer cells

  2000cited by this paper
• Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates.

  2000cited by this paper
• Deletion at 13q21 is associated with aggressive prostate cancers.

  2000cited by this paper
• Expression of the multidrug resistance gene in human prostate cancer.

  2000cited by this paper
• Percentage of Cancer on Biopsy Cores Accurately Predicts Extracapsular Extension and Biochemical Relapse after Radical Prostatectomy for T1–T2 Prostate Cancer

  2000cited by this paper
• Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy

  2000cited by this paper
• Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy.

  2000cited by this paper
• Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.

  2000cited by this paper
• Recent advances in the histopathology and molecular biology of prostate cancer

  2000cited by this paper
• Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

  2000cited by this paper
• Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

  2000cited by this paper
• The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.

  2000cited by this paper
• Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression*

  2000cited by this paper
• Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma.

  2000cited by this paper
• Identification of Genetic Markers for Prostatic Cancer Progression

  2000cited by this paper
• Transforming growth factor-beta1 and prostate cancer.

  2000cited by this paper
• Lymphovascular invasion as a predictor of disease progression in prostate cancer.

  2000cited by this paper
• Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.

  2000cited by this paper
• Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

  2000cited by this paper
• Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target.

  2000cited by this paper
• Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

  2000cited by this paper
• Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7

  2000cited by this paper
• Development of markers of prostate cancer metastasis. Review and perspective.

  2000cited by this paper
• Changes in cell proliferation and apoptosis during local progression of prostate cancer.

  2000cited by this paper
• Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

  2000cited by this paper
• Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31.

  2000cited by this paper
• 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer.

  2000cited by this paper
• p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.

  2000cited by this paper
• Prostate tumor progression and prognosis. interplay of tumor and host factors.

  2000cited by this paper
• The role of E-cadherin-catenin complex: more than an intercellular glue?

  2000cited by this paper
• Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.

  2000cited by this paper
• Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.

  2000cited by this paper
• Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.

  2000cited by this paper
• FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy

  2000cited by this paper
• Telomerase activity in needle biopsies from prostate cancer and benign prostates

  2000cited by this paper
• Aneuploidy of Chromosome 9 and the Tumor Suppressor Genes p16INK4 and p15INK4B Detected by in situ Hybridization in Locally Advanced Prostate Cancer

  2000cited by this paper
• The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system.

  2000cited by this paper
• Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region

  2000cited by this paper
• Cytokine variations in patients with hormone treated prostate cancer.

  2000cited by this paper
• Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting.

  2000cited by this paper
• The Role of E-Cadherin-Catenin Complex: More Than an Intercellular Glue?

  2000cited by this paper
• Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

  2000cited by this paper
• Analysis of cyclin‐dependent kinase inhibitor expression and methylation patterns in human prostate cancers

  2000cited by this paper
• College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants.

  2000cited by this paper
• Her-2-neu expression and progression toward androgen independence in human prostate cancer.

  2000cited by this paper
• Nuclear morphometry predicts disease‐free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy

  1999cited by this paper
• Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

  1999cited by this paper
• Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

  1999cited by this paper
• Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.

  1999cited by this paper
• p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

  1999cited by this paper
• Correlation of margin status and extraprostatic extension with progression of prostate carcinoma

  1999cited by this paper
• Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.

  1999cited by this paper
• Contemporary results of anatomic radical prostatectomy

  1999cited by this paper
• Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.

  1999cited by this paper
• Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

  1999cited by this paper
• Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients

  1999cited by this paper
• Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade?

  1999cited by this paper
• CD44 cell adhesion molecules.

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer.

  1999cited by this paper
• Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

  1999cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

  1998cited by this paper
• Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.

  1998cited by this paper
• Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

  1998cited by this paper
• Correlation of color doppler flow in the prostate with tissue microvascularity

  1998cited by this paper
• Low p27 expression predicts poor disease-free survival in patients with prostate cancer.

  1998cited by this paper
• Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis.

  1998cited by this paper
• The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma

  1997cited by this paper
• Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance.

  1997cited by this paper
• Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate

  1997cited by this paper
• Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

  1997cited by this paper
• Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue.

  1997cited by this paper
• Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival.

  1997cited by this paper
• Cellular adhesion molecules in urologic malignancies.

  1997cited by this paper
• Oncogenes and tumor suppressor genes in prostate cancer: a review.

  1997cited by this paper
• Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings.

  1997cited by this paper
• HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

  1997cited by this paper
• Signet-ring carcinoma of the prostate.

  1996cited by this paper
• Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up.

  1996cited by this paper
• Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen

  1996cited by this paper

• A multivariate curve resolution analysis of multicenter proton spectroscopic imaging of the prostate for cancer localization and assessment of aggressiveness

  2023cites this paper
• HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA

  2022cites this paper
• Altholactone Inhibits NF-κB and STAT3 Activation and Induces Reactive Oxygen Species-Mediated Apoptosis in Prostate Cancer DU145 Cells

  2017cites this paper
• Ellagic acid: cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines.

  2013cites this paper
• Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.

  2011cites this paper
• Diagnostic biomarkers of prostate cancer

  2011cites this paper
• Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis.

  2010influential citation
• Neuroendocrine differentiation in the progression of prostate cancer

  2009cites this paper
• The harmful health effects of recreational ecstasy: a systematic review of observational evidence.

  2009cites this paper
• Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.

  2008cites this paper
• Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study.

  2008cites this paper
• Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer  

  2008cites this paper
• Neuroendocrine differentiation in stage D2 prostate cancers

  2008cites this paper
• Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation

  2008cites this paper
• Prognostic factors in prostate cancer.

  2007cites this paper
• Molecular markers and mortality in prostate cancer

  2007cites this paper
• RNA interference‐mediated silencing of the PAR gene inhibits the growth of PC3 cells via the induction of G2/M cell cycle arrest and apoptosis

  2007cites this paper
• Protein Expression In Prostate Cancer

  2006cites this paper
• Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.

  2005cites this paper
• Biomarkers for the detection and prognosis of prostate cancer

  2005cites this paper
• Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens

  2005influential citation
• A STUDY OF THE TRANSITION FROM PREMALIGNANCY TO CLINICAL PROSTATE CANCER

  2005cites this paper
• Proteomic Approaches to Problem Solving in Prostate Cancer

  2005cites this paper
• A retrospective histopathological study and selected molecular genetics of archival prostatic cancer tissue

  2005cites this paper
• The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.

  2004cites this paper
• DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer

  2004cites this paper
• EXPRESIÓN DE LOS FACTORES ANGIOGÉNICOS VEGF Y bFGF, Y DE LOS RECEPTORES Flt-1 Y FLK/ KDR EN LA NEOPLASIA INTRAEPITELIAL PROSTÁTICA

  2004cites this paper
• Gleason grading and prognostic factors in carcinoma of the prostate

  2004cites this paper
• Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma.

  2003cites this paper
• Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms

  2003cites this paper
• Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma

  2003cites this paper
• Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

  2003cites this paper
• Elevated E-Cadherin and α/β-Catenin Expression after Androgen Deprivation Therapy in Prostate Adenocarcinoma

  2003cites this paper
• Functional genomics guided with MR imaging: mouse tumor model study.

  2003cites this paper
• Molecular and genetic prognostic factors of prostate cancer

  2003cites this paper
• Heparanase-1 gene expression in normal, hyperplastic and neoplastic prostatic tissue.

  2003cites this paper